Tonsillitis Treatments

Find Tonsillitis Treatments

Generic Name

Clarithromycin

FDA approval date: August 25, 2005
Classification: Macrolide Antimicrobial
Form: Tablet, For

What is Clarithromycin?

Clarithromycin tablets are a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults.
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL

Summary: The goal of this clinical trial is to assess whether clarithromycin, given as an adjunct to standard-of-care antibiotic therapy, can reduce the risk of new infections and secondary sepsis in adult patients hospitalized with community-acquired pneumonia (CAP), sepsis, and sepsis-induced immunoparalysis (SII). The primary objective is to evaluate the effect of clarithromycin on the incidence of new ...

Efficacy and Safety of Linarazen Gluconate Capsules Combined With Amoxicillin (Dual-Drug Therapy) Versus Bismuth-Containing Quadruple Therapy for First-Line Eradication of Helicobacter Pylori Infection: A Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Controlled Study

Summary: This clinical trial aims to compare the efficacy of the dual therapy regimen of linralase glutarate capsules and amoxicillin versus the quadruple therapy regimen containing bismuth for the first-line eradication of Helicobacter pylori infection. The primary questions this trial aims to address include: 1. Whether the linalarenate glutarate capsule-amoxicillin dual-drug regimen is non-inferior to t...

Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection

Summary: Treatment of Mycobacterium xenopi (MX) lung disease is not-well- tolerated and concerned a growing number of patients, especially with chronic pulmonary diseases or immunosuppression. The outcome of these patients is poor, and treatment is very long. Indeed, this duration is based on the date of sputum conversion. Treatment should be continued until 12 months after sputum conversion. In the vast m...